Pharmaceutical

Prodigy Biotech Enters into a Partnership Agreement with Leading Cancer Center

To Advance Products to Improve Outcomes in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

/

West Chester, Pennsylvania, United States Prodigy is the first company to join the MSK Therapeutic Accelerator. The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024. Prodigy and Memorial Sloan Kettering Cancer Center (MSK) will co-develop a product targeting Enterococcus sp. to treat microbial […]

Prodigy Biotech Enters into a Partnership Agreement with Leading Cancer Center

To Advance Products to Improve Outcomes in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Read More »

Lyrus Receives US FDA Approval for Critical UTI Treatment in the US

/

Bengaluru, Karnataka, India The U.S. Food and Drug Administration (FDA) has approved Lyrus Life Sciences’s Abbreviated New Drug Application (ANDA) for ‘Methenamine Hippurate Tablets USP, 1 gram’, an AB-rated, substitutable generic version of Hiprex® from Validus Pharmaceuticals LLC which is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy

Lyrus Receives US FDA Approval for Critical UTI Treatment in the US Read More »

CEPI to Support Development of Self Amplifying mRNA Vaccine Technology for Use Against Disease X

/

OSLO, Norway CEPI to provide funding of up to US$3.6 million to advance the development of Gennova Biopharmaceutical’s self-amplifying thermostable mRNA vaccine platform to develop vaccine candidates against Disease X. Funding will support optimisation of the technology platform to enhance immunogenicity. The Coalition for Epidemic Preparedness Innovations (CEPI) and Pune-based Gennova Biopharmaceuticals Ltd, today announced

CEPI to Support Development of Self Amplifying mRNA Vaccine Technology for Use Against Disease X Read More »

Public Health Initiatives by Takeda to Strengthen Health System for Rare Diseases in India

/

New Delhi, Delhi, India Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Private Limited), a global values-based, R&D-driven biopharmaceutical leader conducted dissemination of its public health initiatives in strengthening the health system for rare diseases (RD) in India. These initiatives aim to improve access to healthcare for rare disease patients who otherwise

Public Health Initiatives by Takeda to Strengthen Health System for Rare Diseases in India Read More »

Ready to Take Your PR and Media Visibility to the next Level?

Our team is dedicated to helping you achieve your goals of increased PR and media visibility. By filling out this form, you’ll be taking the first step towards taking your brand or business to the next level. 

Our experts will review your submission and get back to you as soon as possible with personalized recommendations and a plan of action. Let’s work together to get the exposure and recognition you deserve!

Let’s talk